{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:51:55Z","timestamp":1784375515842,"version":"3.55.0"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.intimp.2022.108794","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T11:53:57Z","timestamp":1651319637000},"page":"108794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["An update on novel therapeutic intervention in Rheumatoid arthritis"],"prefix":"10.1016","volume":"109","author":[{"given":"Pritha","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqsa","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankalp","family":"Gharat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Godad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Kale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.108794_b0005","article-title":"Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells."},{"key":"10.1016\/j.intimp.2022.108794_b0010","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00281-017-0623-3","article-title":"Future therapeutic targets in rheumatoid arthritis?","volume":"39","author":"Cheung","year":"2017","journal-title":"Seminars in Immunopathology."},{"key":"10.1016\/j.intimp.2022.108794_b0015","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/acr.20041","article-title":"Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001\u20132005","volume":"62","author":"Sacks","year":"2010","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"Suppl 2","key":"10.1016\/j.intimp.2022.108794_b0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/rheumatology\/39.suppl_2.3","article-title":"Epidemiology of rheumatic diseases","volume":"39","author":"Sangha","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2022.108794_b0025","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/art.27425","article-title":"Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955\u20132007","volume":"62","author":"Myasoedova","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2022.108794_b0030","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrrheum.2015.40","article-title":"Atherosclerosis in rheumatoid arthritis: is it all about inflammation?","volume":"11","author":"Skeoch","year":"2015","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.intimp.2022.108794_b0035","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","article-title":"Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0040","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.intimp.2022.108794_b0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res."},{"key":"10.1016\/j.intimp.2022.108794_b0050","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.iac.2017.01.002","article-title":"Immune Mechanisms and Novel Targets in Rheumatoid Arthritis","volume":"37","author":"Venuturupalli","year":"2017","journal-title":"Immunology and Allergy Clinics of North America."},{"key":"10.1016\/j.intimp.2022.108794_b0055","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.intimp.2022.108794_b0060","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.coi.2013.09.018","article-title":"Autoimmunity to Citrullinated Proteins and the Initiation of Rheumatoid Arthritis","volume":"25","author":"Holers","year":"2013","journal-title":"Curr Opin Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0065","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12016-014-8459-2","article-title":"Citrullinated Autoantigens: From Diagnostic Markers to Pathogenetic Mechanisms","volume":"49","author":"Muller","year":"2015","journal-title":"Clin Rev Allergy Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0070","doi-asserted-by":"crossref","unstructured":"M.C. Lu, N.S. Lai, H.C. Yu, H. bin Huang, S.C. Hsieh, C.L. Yu, Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte\/macrophages and stimulate tumor necrosis factor alpha production, Arthritis Rheum. 62 (2010) 1213\u20131223. 10.1002\/ART.27386.","DOI":"10.1002\/art.27386"},{"issue":"2010","key":"10.1016\/j.intimp.2022.108794_b0075","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2022.108794_b0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0085","doi-asserted-by":"crossref","unstructured":"J.A. Singh, K.G. Saag, S.L. Bridges, E.A. Akl, R.R. Bannuru, M.C. Sullivan, E. Vaysbrot, C. McNaughton, M. Osani, R.H. Shmerling, J.R. Curtis, D.E. Furst, D. Parks, A. Kavanaugh, J. O\u2019Dell, C. King, A. Leong, E.L. Matteson, J.T. Schousboe, B. Drevlow, S. Ginsberg, J. Grober, E.W. St.Clair, E. Tindall, A.S. Miller, T. McAlindon, 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, Arthritis Care & Research. 68 (2016) 1\u201325. 10.1002\/acr.22783.","DOI":"10.1002\/art.39480"},{"key":"10.1016\/j.intimp.2022.108794_b0090","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1002\/art.20583","article-title":"Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action","volume":"50","author":"Buttgereit","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2022.108794_b0095","doi-asserted-by":"crossref","unstructured":"P.M. Brown, A.G. Pratt, J.D. Isaacs, Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers, Nature Reviews Rheumatology 2016 12:12. 12 (2016) 731\u2013742. 10.1038\/nrrheum.2016.175.","DOI":"10.1038\/nrrheum.2016.175"},{"key":"10.1016\/j.intimp.2022.108794_b0100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/14740338.2011.529898","article-title":"Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity","volume":"10","author":"Linares","year":"2011","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.intimp.2022.108794_b0105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","article-title":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases","volume":"23","author":"Rainsford","year":"2015","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.intimp.2022.108794_b0110","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/clim.1999.4777","article-title":"Mechanism of action for leflunomide in rheumatoid arthritis","volume":"93","author":"Fox","year":"1999","journal-title":"Clinical Immunology."},{"key":"10.1016\/j.intimp.2022.108794_b0115","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/art.11015","article-title":"The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study","volume":"48","author":"Kalden","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2022.108794_b0120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cyto.2017.04.012","article-title":"Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines","volume":"98","author":"Kim","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2022.108794_b0125","first-page":"2134","article-title":"Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies","volume":"54","author":"Cavalli","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2022.108794_b0130","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.clinthera.2012.02.014","article-title":"Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic targeting the Interleukin-6 Receptor","volume":"34","author":"Navarro-Mill\u00e1n","year":"2012","journal-title":"Clin Ther."},{"key":"10.1016\/j.intimp.2022.108794_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00384","article-title":"T Cell Migration in Rheumatoid Arthritis","volume":"6","author":"Mellado","year":"2015","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0140","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2022.108794_b0145","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/annrheumdis-2013-204020","article-title":"Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000\u20132010","volume":"74","author":"Aga","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0150","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","article-title":"Inequities in access to biologic and synthetic DMARDs across 46 European countries","volume":"73","author":"Putrik","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0155","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and Management of Rheumatoid Arthritis: A Review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA - Journal of the American Medical Association."},{"key":"10.1016\/j.intimp.2022.108794_b0160","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/annrheumdis-2018-213687","article-title":"Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey","volume":"77","author":"Roodenrijs","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0165","doi-asserted-by":"crossref","unstructured":"L. Bazzichi, P. Rossi, C. Giacomelli, F. de Feo, F. Bobbio-Pallavicini, A. Rossi, C. Baldini, A. Consensi, M. Doveri, C. Bonino, M. Mazzantini, A. della Rossa, C. Montecucco, S. Bombardieri, A proposal of simple calculation (ERI calculator) to predict the early response to TNF-\u03b1 blockers therapy in rheumatoid arthritis, Rheumatol Int. 32 (2012) 349\u2013356. 10.1007\/S00296-010-1619-7.","DOI":"10.1007\/s00296-010-1619-7"},{"key":"10.1016\/j.intimp.2022.108794_b0170","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1152\/physiolgenomics.00127.2010","article-title":"Gene expression profiling in peripheral blood cells of patients with rheumatoid arthritis in response to anti-TNF-alpha treatments","volume":"43","author":"Meugnier","year":"2011","journal-title":"Physiol Genomics."},{"key":"10.1016\/j.intimp.2022.108794_b0175","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/rheumatology\/ket224","article-title":"Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis","volume":"52","author":"Ranganath","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2022.108794_b0180","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"The Lancet."},{"key":"10.1016\/j.intimp.2022.108794_b0185","first-page":"679","article-title":"Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor \u03b1 Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis, Arthritis","volume":"70","author":"Burmester","year":"2018","journal-title":"Rheumatol."},{"key":"10.1016\/j.intimp.2022.108794_b0190","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0742-y","article-title":"Phosphatase and tensin homolog (PTEN) in antigen-presenting cells controls Th17-mediated autoimmune arthritis","volume":"17","author":"Bl\u00fcml","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.intimp.2022.108794_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-5890(00)00018-3","article-title":"The Jak-STAT pathway","volume":"37","author":"Imada","year":"2000","journal-title":"Mol Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0200","doi-asserted-by":"crossref","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: from interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J Biol Chem."},{"key":"10.1016\/j.intimp.2022.108794_b0205","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J Cell Sci."},{"key":"10.1016\/j.intimp.2022.108794_b0210","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/08977194.2012.660936","article-title":"Biology and significance of the JAK\/STAT signalling pathways","volume":"30","author":"Kiu","year":"2012","journal-title":"Growth Factors"},{"key":"10.1016\/j.intimp.2022.108794_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The molecular regulation of Janus kinase (JAK) activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem J."},{"key":"10.1016\/j.intimp.2022.108794_b0220","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/ar1197","article-title":"Signaling by STATs","volume":"6","author":"Ivashkiv","year":"2004","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.intimp.2022.108794_b0225","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in Immunity, Immunodeficiency, and Cancer","volume":"368","author":"O\u2019Shea","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.intimp.2022.108794_b0230","article-title":"STAT heterodimers in immunity: A mixed message or a unique signal?","volume":"2","author":"Delgoffe","year":"2013","journal-title":"JAKSTAT."},{"key":"10.1016\/j.intimp.2022.108794_b0235","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.3390\/cancers3043856","article-title":"Cytokines in cancer immunotherapy","volume":"3","author":"Lee","year":"2011","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.intimp.2022.108794_b0240","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.2174\/0929867323666160607120124","article-title":"Targeting the Microglial Signaling Pathways: New Insights in the Modulation of Neuropathic Pain","volume":"23","author":"Popiolek-Barczyk","year":"2016","journal-title":"Curr Med Chem."},{"key":"10.1016\/j.intimp.2022.108794_b0245","doi-asserted-by":"crossref","unstructured":"R.F. van Vollenhoven, R. Fleischmann, S. Cohen, E.B. Lee, J.A. Garc\u00eda Meijide, S. Wagner, S. Forejtova, S.H. Zwillich, D. Gruben, T. Koncz, G. v. Wallenstein, S. Krishnaswami, J.D. Bradley, B. Wilkinson, Tofacitinib or adalimumab versus placebo in rheumatoid arthritis, N Engl J Med. 367 (2012) 508\u2013519. 10.1056\/NEJMOA1112072.","DOI":"10.1056\/NEJMoa1112072"},{"key":"10.1016\/j.intimp.2022.108794_b0250","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2022.108794_b0255","doi-asserted-by":"crossref","unstructured":"R. Fleischmann, J. Kremer, J. Cush, H. Schulze-Koops, C.A. Connell, J.D. Bradley, D. Gruben, G. v. Wallenstein, S.H. Zwillich, K.S. Kanik, Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis, N Engl J Med. 367 (2012) 495\u2013507. 10.1056\/NEJMOA1109071.","DOI":"10.1056\/NEJMoa1109071"},{"key":"10.1016\/j.intimp.2022.108794_b0260","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.intimp.2022.108794_b0265","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.intimp.2022.108794_b0270","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0275","doi-asserted-by":"crossref","unstructured":"J.J. O\u2019Shea, D.M. Schwartz, A. v. Villarino, M. Gadina, I.B. McInnes, A. Laurence, The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention, Annu Rev Med. 66 (2015) 311. 10.1146\/ANNUREV-MED-051113-024537.","DOI":"10.1146\/annurev-med-051113-024537"},{"key":"10.1016\/j.intimp.2022.108794_b0280","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3390\/ijms16010887","article-title":"Cytokine-modulating strategies and newer cytokine targets for arthritis therapy","volume":"16","author":"Venkatesha","year":"2014","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.intimp.2022.108794_b0285","first-page":"506","article-title":"Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment, Arthritis","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Rheumatol."},{"key":"10.1016\/j.intimp.2022.108794_b0290","unstructured":"G. MC, K. J, Z. O, L. C, K. M, X. L, B. SD, K. AE, C. TE, R. TP, M. WL, de B. S, S. DE, S. JS, Baricitinib in Patients with Refractory Rheumatoid Arthritis, N Engl J Med. 374 (2016) 60\u201361. 10.1056\/NEJMOA1507247."},{"key":"10.1016\/j.intimp.2022.108794_b0295","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2022.108794_b0300","doi-asserted-by":"crossref","unstructured":"A. Barbulescu, J. Askling, K. Chatzidionysiou, H. Forsblad-d\u2019Elia, A. Kastbom, U. Lindstr\u00f6m, C. Turesson, T. Frisell, Effectiveness of baricitinib and tofacitinib compared to bDMARDs in RA: results from a cohort study using nationwide Swedish register data, Rheumatology (Oxford). (2022). 10.1093\/RHEUMATOLOGY\/KEAC068.","DOI":"10.1093\/rheumatology\/keac068"},{"key":"10.1016\/j.intimp.2022.108794_b0305","doi-asserted-by":"crossref","unstructured":"J. Galloway, F. Atzeni, JAK inhibitors: special issue foreword, 10.1080\/1744666X.2022.2050596. 18 (2022) 179\u2013180. 10.1080\/1744666X.2022.2050596.","DOI":"10.1080\/1744666X.2022.2050596"},{"key":"10.1016\/j.intimp.2022.108794_b0310","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/337471a0","article-title":"Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate","volume":"337","author":"Bussolino","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2022.108794_b0315","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nri2356","article-title":"Colony-stimulating factors in inflammation and autoimmunity","volume":"8","author":"Hamilton","year":"2008","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0320","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cell.2008.05.053","article-title":"The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation","volume":"134","author":"Hansen","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.108794_b0325","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cytogfr.2013.03.002","article-title":"Signalling by the \u03b2c family of cytokines","volume":"24","author":"Hercus","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2022.108794_b0330","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood-2008-12-164004","article-title":"The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease","volume":"114","author":"Hercus","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2022.108794_b0335","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1615\/CritRevImmunol.v25.i5.50","article-title":"Functions of granulocyte-macrophage colony-stimulating factor","volume":"25","author":"Fleetwood","year":"2005","journal-title":"Crit Rev Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0340","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.4049\/jimmunol.173.7.4643","article-title":"Stimulus-dependent requirement for granulocyte-macrophage colony-stimulating factor in inflammation","volume":"173","author":"Cook","year":"2004","journal-title":"J Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0345","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrrheum.2015.161","article-title":"Targeting GM-CSF in inflammatory diseases","volume":"12","author":"Wicks","year":"2016","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.intimp.2022.108794_b0350","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF00262295","article-title":"Measurement of colony-stimulating factors in synovial fluid: potential clinical value","volume":"14","author":"Bell","year":"1995","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.intimp.2022.108794_b0355","unstructured":"F Berenbaum, G Rajzbaum, B Amor, A Toubert, Evidence for GM-CSF receptor expression in synovial tissue. An analysis by semi-quantitative polymerase chain reaction on rheumatoid arthritis and osteoarthritis synovial biopsies - PubMed, (1994). https:\/\/pubmed.ncbi.nlm.nih.gov\/8049356\/ (accessed February 27, 2022)."},{"key":"10.1016\/j.intimp.2022.108794_b0360","doi-asserted-by":"crossref","DOI":"10.1186\/ar2079","article-title":"MLN51 and GM-CSF involvement in the proliferation of fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis","volume":"8","author":"Jang","year":"2006","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.intimp.2022.108794_b0365","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/ard.2006.057182","article-title":"GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice","volume":"66","author":"Plater-Zyberk","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0370","doi-asserted-by":"crossref","unstructured":"F. Hua, P. v. Henstock, B. Tang, ERK activation by GM-CSF reduces effectiveness of p38 inhibitor on inhibiting TNFalpha release, Int Immunopharmacol. 10 (2010) 730\u2013737. 10.1016\/J.INTIMP.2010.04.002.","DOI":"10.1016\/j.intimp.2010.04.002"},{"key":"10.1016\/j.intimp.2022.108794_b0375","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1039\/c002848g","article-title":"Elevated GM-CSF and IL-1beta levels compromise the ability of p38 MAPK inhibitors to modulate TNFalpha levels in the human monocytic\/macrophage U937 cell line","volume":"6","author":"Espelin","year":"2010","journal-title":"Mol Biosyst."},{"key":"10.1016\/j.intimp.2022.108794_b0380","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0683-5","volume":"17","author":"van Nieuwenhuijze","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.intimp.2022.108794_b0385","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/ard.2007.085431","article-title":"Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model","volume":"68","author":"Plater-Zyberk","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0390","doi-asserted-by":"crossref","unstructured":"Resistance of Rheumatoid Synovial Dendritic Cells to the Immunosuppressive Effects of IL-10 | The Journal of Immunology, (n.d.). https:\/\/www.jimmunol.org\/content\/163\/10\/5599.long (accessed February 27, 2022).","DOI":"10.4049\/jimmunol.163.10.5599"},{"key":"10.1016\/j.intimp.2022.108794_b0395","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2003.010033","article-title":"High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcgammaR triggering","volume":"63","author":"Radstake","year":"2004","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0400","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.4049\/jimmunol.169.11.6625","article-title":"Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages","volume":"169","author":"Tsark","year":"2002","journal-title":"J Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0405","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/annrheumdis-2012-201703","article-title":"Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain","volume":"72","author":"Cook","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0410","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/ard.2010.146225","article-title":"Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-\u03b1, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study","volume":"70","author":"Burmester","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0415","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2012-202450","article-title":"Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0420","unstructured":"Ali Berkant Avci, Eugen Feist, Gerd-R\u00fcdiger Burmester, Targeting GM-CSF in rheumatoid arthritis, (2016)."},{"key":"10.1016\/j.intimp.2022.108794_b0425","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/annrheumdis-2013-204816","article-title":"MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib\/IIa randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"74","author":"Behrens","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0430","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.molimm.2013.05.002","article-title":"GM-CSF as a therapeutic target in inflammatory diseases","volume":"56","author":"van Nieuwenhuijze","year":"2013","journal-title":"Mol Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0435","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1136\/annrheumdis-2014-205234","article-title":"Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis","volume":"74","author":"Greven","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0440","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/rheumatology\/kex383","article-title":"Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis","volume":"57","author":"Guo","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2022.108794_b0445","doi-asserted-by":"crossref","unstructured":"P. Jiang, K. Wei, J. Zhao, Y. Jin, C. Chang, R. Zhang, L. Xu, L. Xu, Y. Shi, S. Guo, S.J. Schrodi, D. He, Trends of Treatment Development in Rheumatoid Arthritis: Promise, Progress, and Challenges, (2022). 10.20944\/PREPRINTS202203.0071.V1.","DOI":"10.20944\/preprints202203.0071.v2"},{"key":"10.1016\/j.intimp.2022.108794_b0450","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/14397595.2014.896448","article-title":"Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study","volume":"25","author":"Takeuchi","year":"2015","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.intimp.2022.108794_b0455","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/art.40323","article-title":"A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis","volume":"70","author":"Weinblatt","year":"2018","journal-title":"Arthritis and Rheumatology."},{"key":"10.1016\/j.intimp.2022.108794_b0460","unstructured":"Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFR\u00c3\u00a1 - ACR Meeting Abstracts, (n.d.). https:\/\/acrabstracts.org\/abstract\/rapid-onset-of-clinical-benefit-is-associated-with-a-reduction-in-validated-biomarkers-of-disease-in-patients-with-rheumatoid-arthritis-treated-with-mavrilimumab-a-human-monoclonal-antibody-targeting\/ (accessed February 27, 2022)."},{"key":"10.1016\/j.intimp.2022.108794_b0465","doi-asserted-by":"crossref","unstructured":"X. Guo, D. Sinibaldi, M. Kuziora, P. Brohawn, P.C. Ryan, A.C. Bay-Jensen, M.A. Karsdal, L.K. Roskos, W.I. White, SAT0212\u2005Sustained Response to Mavrilimumab in Rheumatoid Arthritis Patients VIA Suppression of Macrophage and T Cells, Annals of the Rheumatic Diseases. 74 (2015) 734\u2013734. 10.1136\/ANNRHEUMDIS-2015-EULAR.4254.","DOI":"10.1136\/annrheumdis-2015-eular.4254"},{"key":"10.1016\/j.intimp.2022.108794_b0470","unstructured":"Analysis of Patient-Reported Outcomes during Treatment with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFR\u00e1, in the Randomized Phase 2b Earth Explorer 1 Study - ACR Meeting Abstracts, (n.d.). https:\/\/acrabstracts.org\/abstract\/analysis-of-patient-reported-outcomes-during-treatment-with-mavrilimumab-a-human-monoclonal-antibody-targeting-gm-csfra-in-the-randomized-phase-2b-earth-explorer-1-study\/ (accessed February 27, 2022)."},{"key":"10.1016\/j.intimp.2022.108794_b0475","unstructured":"A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis - Full Text View - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01715896 (accessed February 27, 2022)."},{"key":"10.1016\/j.intimp.2022.108794_b0480","unstructured":"Long-term Safety and Efficacy of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-\u03b1 (GM\u2013CSFR-\u03b1) Monoclonal Antibody, in Patients with Rheumatoid Arthritis (RA) - ACR Meeting Abstracts, (n.d.). https:\/\/acrabstracts.org\/abstract\/long-term-safety-and-efficacy-of-mavrilimumab-a-fully-human-granulocyte-macrophage-colony-stimulating-factor-receptor-gmcsfr-monoclonal-antibody-in-patients-with-rheumatoid\/ (accessed February 27, 2022)."},{"key":"10.1016\/j.intimp.2022.108794_b0485","doi-asserted-by":"crossref","first-page":"733.1-733","DOI":"10.1136\/annrheumdis-2015-eular.1602","article-title":"SAT0210 First-in-Patient Study of Namilumab, an Anti-GM-CSF Monoclonal Antibody, in Active Rheumatoid Arthritis: Results of the Priora Phase IB Study","volume":"74","author":"Huizinga","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0490","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1006\/smim.1998.0123","article-title":"Btk function in B cell development and response","volume":"10","author":"Satterthwaite","year":"1998","journal-title":"Semin Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0495","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-0988-z","article-title":"HM71224, a novel Bruton\u2019s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis","volume":"18","author":"Park","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.intimp.2022.108794_b0500","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1124\/jpet.111.181545","article-title":"Antiarthritis effect of a novel Bruton\u2019s tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic\/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy","volume":"338","author":"Liu","year":"2011","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.intimp.2022.108794_b0505","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/rheumatology\/kes367","article-title":"Novel small molecule therapeutics in rheumatoid arthritis","volume":"52","author":"Kelly","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2022.108794_b0510","first-page":"171","article-title":"Role of Bruton\u2019s tyrosine kinase in B cell development","volume":"8","author":"Maas","year":"2001","journal-title":"Dev Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0515","doi-asserted-by":"crossref","unstructured":"A.J. Mohamed, L. Yu, C.M. B\u00e4ckesj\u00f6, L. Vargas, R. Faryal, A. Aints, B. Christensson, A. Bergl\u00f6f, M. Vihinen, B.F. Nore, C.I. Edvard Smith, Bruton\u2019s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain, Immunol Rev. 228 (2009) 58\u201373. 10.1111\/J.1600-065X.2008.00741.X.","DOI":"10.1111\/j.1600-065X.2008.00741.x"},{"key":"10.1016\/j.intimp.2022.108794_b0520","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1385\/IR:23:2-3:147","article-title":"Regulation of B lymphocyte development and activation by Bruton\u2019s tyrosine kinase","volume":"23","author":"Khan","year":"2001","journal-title":"Immunol Res."},{"key":"10.1016\/j.intimp.2022.108794_b0525","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.113.203489","article-title":"Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans","volume":"346","author":"Evans","year":"2013","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.intimp.2022.108794_b0530","doi-asserted-by":"crossref","unstructured":"Z. Pan, H. Scheerens, S.J. Li, B.E. Schultz, P.A. Sprengeler, L.C. Burrill, R. v. Mendonca, M.D. Sweeney, K.C.K. Scott, P.G. Grothaus, D.A. Jeffery, J.M. Spoerke, L.A. Honigberg, P.R. Young, S.A. Dalrymple, J.T. Palmer, Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase, ChemMedChem. 2 (2007) 58\u201361. 10.1002\/CMDC.200600221.","DOI":"10.1002\/cmdc.200600221"},{"key":"10.1016\/j.intimp.2022.108794_b0535","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2022.108794_b0540","first-page":"3551","article-title":"Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition, Journal for Immunotherapy of","volume":"10","author":"Henderson Berg","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2022.108794_b0545","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"296","author":"Cantley","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.intimp.2022.108794_b0550","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1242\/jcs.00609","article-title":"The phosphoinositide (PI) 3-kinase family","volume":"116","author":"Foster","year":"2003","journal-title":"J Cell Sci."},{"key":"10.1016\/j.intimp.2022.108794_b0555","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood-2005-07-3041","article-title":"Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells","volume":"107","author":"Bilancio","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2022.108794_b0560","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1128\/MCB.22.24.8580-8591.2002","article-title":"Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex","volume":"22","author":"Jou","year":"2002","journal-title":"Mol Cell Biol."},{"key":"10.1016\/j.intimp.2022.108794_b0565","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2001104","article-title":"The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development","volume":"3","author":"Ramadani","year":"2010","journal-title":"Sci Signal."},{"key":"10.1016\/j.intimp.2022.108794_b0570","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nm1766","article-title":"Activation of c-kit in dendritic cells regulates T helper cell differentiation and allergic asthma","volume":"14","author":"Krishnamoorthy","year":"2008","journal-title":"Nat Med."},{"key":"10.1016\/j.intimp.2022.108794_b0575","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri2036","article-title":"PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?","volume":"7","author":"Rommel","year":"2007","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0580","doi-asserted-by":"crossref","unstructured":"B.-H. E, C. MR, O. K, The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases, Open Rheumatol J. 6 (2012) 245\u2013258. 10.2174\/1874312901206010245.","DOI":"10.2174\/1874312901206010245"},{"key":"10.1016\/j.intimp.2022.108794_b0585","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm1284","article-title":"Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis","volume":"11","author":"Camps","year":"2005","journal-title":"Nat Med."},{"key":"10.1016\/j.intimp.2022.108794_b0590","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1096\/fj.09-135160","article-title":"PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis","volume":"23","author":"Hayer","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2022.108794_b0595","unstructured":"L. Zou, G. Zhang, L. Liu, C. Chen, X. Cao, J. Cai, Relationship between PI3K pathway and angiogenesis in CIA rat synovium, American Journal of Translational Research. 8 (2016) 3141. \/pmc\/articles\/PMC4969451\/ (accessed February 27, 2022)."},{"key":"10.1016\/j.intimp.2022.108794_b0600","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/PPO.0000000000000167","article-title":"Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma","volume":"22","author":"Sujobert","year":"2016","journal-title":"Cancer J."},{"key":"10.1016\/j.intimp.2022.108794_b0605","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2040620715625966","article-title":"The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia","volume":"7","author":"Nair","year":"2016","journal-title":"Ther Adv Hematol."},{"key":"10.1016\/j.intimp.2022.108794_b0610","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2147\/OTT.S102573","article-title":"Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential","volume":"9","author":"Barrientos","year":"2016","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.intimp.2022.108794_b0615","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","article-title":"Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma","volume":"21","author":"Yang","year":"2015","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.intimp.2022.108794_b0620","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1073\/pnas.231606698","article-title":"Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance","volume":"99","author":"Steinman","year":"2002","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.intimp.2022.108794_b0625","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/B978-0-12-380995-7.00004-5","article-title":"How tolerogenic dendritic cells induce regulatory T cells","volume":"108","author":"Maldonado","year":"2010","journal-title":"Adv Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0630","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.0105-2896.2006.00420.x","article-title":"Interleukin-10-secreting type 1 regulatory T cells in rodents and humans","volume":"212","author":"Roncarolo","year":"2006","journal-title":"Immunol Rev."},{"key":"10.1016\/j.intimp.2022.108794_b0635","unstructured":"Differentiated dendritic cells expressing nuclear RelB are predominantly located in rheumatoid synovial tissue perivascular mononuclear cell aggregates - Pettit - 2000 - Arthritis & Rheumatism - Wiley Online Library, (n.d.). https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/1529-0131(200004)43:4%3C791::AID-ANR9%3E3.0.CO;2-E (accessed February 27, 2022)."},{"key":"10.1016\/j.intimp.2022.108794_b0640","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.4049\/jimmunol.171.11.5736","article-title":"Aberrant extracellular and dendritic cell (DC) surface expression of heat shock protein (hsp)70 in the rheumatoid joint: possible mechanisms of hsp\/DC-mediated cross-priming","volume":"171","author":"Martin","year":"2003","journal-title":"J Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0645","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2353\/ajpath.2008.070703","article-title":"Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP- dendritic cells with distinct cytokine profiles","volume":"172","author":"Lebre","year":"2008","journal-title":"Am J Pathol."},{"key":"10.1016\/j.intimp.2022.108794_b0650","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/ard.2004.023259","article-title":"Inhibition of TNF alpha during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNF alpha blockade in rheumatoid arthritis","volume":"64","author":"van Lieshout","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0655","unstructured":"M. van Oosterhout, E.W. N Levarht, J.K. Sont, T.W. J Huizinga, R.E. M Toes, J.M. van Laar, Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNFa and IL18 but not CXCL12, (n.d.). 10.1136\/ard.2004.024927."},{"key":"10.1016\/j.intimp.2022.108794_b0660","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2119\/molmed.2011.00065","article-title":"Restoring the balance of the autonomic nervous system as an innovative approach to the treatment of rheumatoid arthritis","volume":"17","author":"Koopman","year":"2011","journal-title":"Mol Med."},{"key":"10.1016\/j.intimp.2022.108794_b0665","doi-asserted-by":"crossref","unstructured":"L. v. Borovikova, S. Ivanova, M. Zhang, H. Yang, G.I. Botchkina, L.R. Watkins, H. Wang, N. Abumrad, J.W. Eaton, K.J. Tracey, Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin, Nature. 405 (2000) 458\u2013462. 10.1038\/35013070.","DOI":"10.1038\/35013070"},{"key":"10.1016\/j.intimp.2022.108794_b0670","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature01339","article-title":"Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation","volume":"421","author":"Wang","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2022.108794_b0675","unstructured":"(PDF) The Sympathetic Nerve\u2014An Integrative Interface between Two Supersystems: The Brain and the Immune System, (n.d.). https:\/\/www.researchgate.net\/publication\/12206217_The_Sympathetic_Nerve-An_Integrative_Interface_between_Two_Supersystems_The_Brain_and_the_Immune_System (accessed February 28, 2022)."},{"key":"10.1016\/j.intimp.2022.108794_b0680","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s00296-003-0357-5","article-title":"Heart rate variability in patients with rheumatoid arthritis","volume":"24","author":"Evreng\u00fcl","year":"2004","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.intimp.2022.108794_b0685","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.rdc.2004.09.003","article-title":"Sympathetic neurotransmitters in joint inflammation","volume":"31","author":"Straub","year":"2005","journal-title":"Rheum Dis Clin North Am."},{"key":"10.1016\/j.intimp.2022.108794_b0690","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/14712598.2017.1263614","article-title":"Denosumab: Targeting the RANKL pathway to treat Rheumatoid Arthritis","volume":"17","author":"Chiu","year":"2017","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.intimp.2022.108794_b0695","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/acr.23133","article-title":"Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: A High-Resolution Peripheral Quantitative Computed Tomography Study","volume":"69","author":"Yue","year":"2017","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.intimp.2022.108794_b0700","doi-asserted-by":"crossref","unstructured":"A.J. Templeton, L. Stalder, J. Bernhard, P. Brauchli, S. Gillessen, S. Hayoz, D. Klingbiel, K. Matter-Walstra, B.J.K. Thurlimann, R. von Moos, Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96\/12, REDUSE)., Journal of Clinical Oncology. 32 (2014) TPS5095\u2013TPS5095. 10.1200\/JCO.2014.32.15_SUPPL.TPS5095.","DOI":"10.1200\/jco.2014.32.15_suppl.tps5095"},{"key":"10.1016\/j.intimp.2022.108794_b0705","unstructured":"The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients - Full Text View - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03960554 (accessed April 8, 2022)."},{"key":"10.1016\/j.intimp.2022.108794_b0710","unstructured":"Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant - Full Text View - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03925532 (accessed April 8, 2022)."},{"key":"10.1016\/j.intimp.2022.108794_b0715","unstructured":"Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer - Full Text View - ClinicalTrials.gov, (n.d.). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03324932 (accessed April 8, 2022)."},{"key":"10.1016\/j.intimp.2022.108794_b0720","doi-asserted-by":"crossref","unstructured":"H. Kurinami, M. Shimamura, H. Nakagami, H. Shimizu, H. Koriyama, T. Kawano, K. Wakayama, H. Mochizuki, H. Rakugi, R. Morishita, A Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke, Scientific Reports 2016 6:1. 6 (2016) 1\u201311. 10.1038\/srep38062.","DOI":"10.1038\/srep38062"},{"key":"10.1016\/j.intimp.2022.108794_b0725","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1172\/JCI22513","article-title":"A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss","volume":"116","author":"Aoki","year":"2006","journal-title":"J Clin Invest."},{"key":"10.1016\/j.intimp.2022.108794_b0730","doi-asserted-by":"crossref","first-page":"20281","DOI":"10.1073\/pnas.1011686107","article-title":"Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis","volume":"107","author":"Ta","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.intimp.2022.108794_b0735","doi-asserted-by":"crossref","unstructured":"F. Suo, X. Zhou, R. Setroikromo, W.J. Quax, Receptor Specificity Engineering of TNF Superfamily Ligands, Pharmaceutics 2022, Vol. 14, Page 181. 14 (2022) 181. 10.3390\/PHARMACEUTICS14010181.","DOI":"10.3390\/pharmaceutics14010181"},{"key":"10.1016\/j.intimp.2022.108794_b0740","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/nyas.12815","article-title":"The immunomodulatory function of mesenchymal stem cells: mode of action and pathways","volume":"1351","author":"Uccelli","year":"2015","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.intimp.2022.108794_b0745","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1002\/art.30474","article-title":"Role of mesenchymal stem cells in reestablishing immunologic tolerance in autoimmune rheumatic diseases","volume":"63","author":"MacDonald","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2022.108794_b0750","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/art.22511","article-title":"Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis","volume":"56","author":"Augello","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2022.108794_b0755","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrrheum.2009.178","article-title":"G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis","volume":"5","author":"Cornish","year":"2009","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.intimp.2022.108794_b0760","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0765","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","article-title":"Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis","volume":"26","author":"Alivernini","year":"2020","journal-title":"Nat Med."},{"key":"10.1016\/j.intimp.2022.108794_b0770","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/cei.13098","article-title":"Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells","volume":"193","author":"Alivernini","year":"2018","journal-title":"Clin Exp Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0775","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41584-020-0413-5","article-title":"Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes","volume":"16","author":"Nygaard","year":"2020","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.intimp.2022.108794_b0780","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04310-9","article-title":"Comprehensive epigenetic landscape of rheumatoid arthritis fibroblast-like synoviocytes","volume":"9","author":"Ai","year":"2018","journal-title":"Nat Commun."},{"key":"10.1016\/j.intimp.2022.108794_b0785","doi-asserted-by":"crossref","DOI":"10.1186\/s13072-016-0079-z","article-title":"Epigenetic dynamics of monocyte-to-macrophage differentiation","volume":"9","author":"Wallner","year":"2016","journal-title":"Epigenetics Chromatin."},{"key":"10.1016\/j.intimp.2022.108794_b0790","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.cmet.2016.10.008","article-title":"Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity","volume":"24","author":"Arts","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2022.108794_b0795","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ni.3818","article-title":"Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation","volume":"18","author":"Park","year":"2017","journal-title":"Nat Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0800","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaut.2017.01.002","article-title":"MicroRNA-155 contributes to enhanced resistance to apoptosis in monocytes from patients with rheumatoid arthritis","volume":"79","author":"Rajasekhar","year":"2017","journal-title":"J Autoimmun."},{"key":"10.1016\/j.intimp.2022.108794_b0805","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.834247","article-title":"New Druggable Targets for Rheumatoid Arthritis Based on Insights From Synovial Biology","volume":"13","author":"Sandhu","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0810","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1136\/annrheumdis-2018-eular.2166","article-title":"FRI0118 Dekavil (F8IL10) \u2013 update on the results of clinical trials investigating the immunocytokine in patients with rheumatoid arthritis","volume":"77","author":"Behrens","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0815","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03191127","article-title":"Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis","volume":"31","author":"Tak","year":"2006","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"10.1016\/j.intimp.2022.108794_b0820","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/art.21249","article-title":"Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study","volume":"52","author":"Baslund","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2022.108794_b0825","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000493390","article-title":"Rheumatoid Arthritis: A Brief Overview of the Treatment","volume":"27","author":"Bullock","year":"2018","journal-title":"Med Princ Pract."},{"key":"10.1016\/j.intimp.2022.108794_b0830","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1136\/ard.2010.131235","article-title":"CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial","volume":"69","author":"van Kuijk","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0835","doi-asserted-by":"crossref","DOI":"10.1186\/ar3685","article-title":"Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial","volume":"14","author":"Fleishaker","year":"2012","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.intimp.2022.108794_b0840","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/annrheumdis-2011-201605","article-title":"Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial","volume":"72","author":"Tak","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2019.06.001","article-title":"Circulating microRNA-23b as a new biomarker for rheumatoid arthritis","volume":"712","author":"Liu","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.intimp.2022.108794_b0850","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/14397595.2020.1868675","article-title":"A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.intimp.2022.108794_b0855","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10354-015-0344-y","article-title":"Anti-TNF in rheumatoid arthritis: an overview","volume":"165","author":"Radner","year":"2015","journal-title":"Wien Med Wochenschr."},{"key":"10.1016\/j.intimp.2022.108794_b0860","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/13543784.2020.1752660","article-title":"Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis","volume":"29","author":"Wiese","year":"2020","journal-title":"Expert Opin Investig Drugs."},{"key":"10.1016\/j.intimp.2022.108794_b0865","doi-asserted-by":"crossref","unstructured":"R. Harrington, S.A. al Nokhatha, R. Conway, JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data, J Inflamm Res. 13 (2020) 519\u2013531. 10.2147\/JIR.S219586.","DOI":"10.2147\/JIR.S219586"},{"key":"10.1016\/j.intimp.2022.108794_b0870","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/molehr\/gav056","article-title":"Selective modulation of the prostaglandin F2\u03b1 pathway markedly impacts on endometriosis progression in a xenograft mouse model","volume":"21","author":"Ahmad","year":"2015","journal-title":"Mol Hum Reprod."},{"key":"10.1016\/j.intimp.2022.108794_b0875","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9626427","article-title":"Therapeutic Treatment of Arthritic Mice with 15-Deoxy \u0394 12,14-Prostaglandin J 2 (15d-PGJ 2) Ameliorates Disease through the Suppression of Th17 Cells and the Induction of CD4 + CD25 - FOXP3 + Cells","volume":"2016","author":"Carregaro","year":"2016","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.intimp.2022.108794_b0880","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s00296-004-0563-9","article-title":"Decrease in circulating endothelial cell adhesion molecule and thrombomodulin levels during oral iloprost treatment in rheumatoid arthritis patients: preliminary results","volume":"26","author":"Boehme","year":"2006","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.intimp.2022.108794_b0885","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1537-8","article-title":"Pharmacological characterisation of CR6086, a potent prostaglandin E 2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug","volume":"20","author":"Caselli","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.intimp.2022.108794_b0890","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1476-5381.2010.00647.x","article-title":"A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models","volume":"160","author":"Chen","year":"2010","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.intimp.2022.108794_b0895","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/art.30656","article-title":"Prostaglandin D2 regulates joint inflammation and destruction in murine collagen-induced arthritis","volume":"64","author":"Maicas","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2022.108794_b0900","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/ard.2006.062554","article-title":"Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis","volume":"66","author":"D\u00edaz-Gonz\u00e1lez","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.intimp.2022.108794_b0905","doi-asserted-by":"crossref","unstructured":"M. Xu, R. Hong, X. Zhang, H. Zou, Y. Zhang, Z. Hou, L. Wang, CysLT1 receptor antagonist alleviates pathogenesis of collagen-induced arthritis mouse model, Oncotarget. 8 (2017) 108418\u2013108429. 10.18632\/ONCOTARGET.22664.","DOI":"10.18632\/oncotarget.22664"},{"key":"10.1016\/j.intimp.2022.108794_b0910","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00011-007-7141-z","article-title":"BML-111, a lipoxin receptor agonist, modulates the immune response and reduces the severity of collagen-induced arthritis","volume":"57","author":"Zhang","year":"2008","journal-title":"Inflamm Res."},{"key":"10.1016\/j.intimp.2022.108794_b0915","article-title":"The specific binding of the platelet-activating factor (PAF) receptor antagonist WEB 2086 and the benzodiazepine flunitrazepam to rat hepatocytes","volume":"58","author":"Svetlov","year":"1996","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2022.108794_b0920","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejphar.2019.02.031","article-title":"Anti-oxidant and anti-inflammatory effects of cinnamaldehyde and eugenol on mononuclear cells of rheumatoid arthritis patients","volume":"852","author":"Mateen","year":"2019","journal-title":"Eur J Pharmacol."},{"key":"10.1016\/j.intimp.2022.108794_b0925","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.micpath.2017.02.031","article-title":"Effect of iNOS inhibitor LNMMA along with antibiotics Chloramphenicol or Ofloxacin in murine peritoneal macrophages regulates S.aureus infection as well as inflammation: An in vitro study","volume":"105","author":"Dey","year":"2017","journal-title":"Microb Pathog."},{"key":"10.1016\/j.intimp.2022.108794_b0930","doi-asserted-by":"crossref","DOI":"10.1186\/ar4034","article-title":"Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled study","volume":"14","author":"Seymour","year":"2012","journal-title":"Arthritis Research and Therapy."},{"key":"10.1016\/j.intimp.2022.108794_b0935","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.pbb.2011.06.022","article-title":"Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice","volume":"99","author":"Kinsey","year":"2011","journal-title":"Pharmacol Biochem Behav."},{"key":"10.1016\/j.intimp.2022.108794_b0940","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01027","article-title":"Cannabinoid Receptor 2 Agonist JWH-015 Inhibits Interleukin-1\u03b2-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts and in Adjuvant Induced Arthritis Rat via Glucocorticoid Receptor","volume":"10","author":"Fechtner","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2022.108794_b0945","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/mol.117.110841","article-title":"N- Acyl Amino Acids (Elmiric Acids): Endogenous Signaling Molecules with Therapeutic Potential","volume":"93","author":"Burstein","year":"2018","journal-title":"Mol Pharmacol."},{"key":"10.1016\/j.intimp.2022.108794_b0950","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/rheumatology\/ket447","article-title":"Expression of cannabinoid receptor 2 and its inhibitory effects on synovial fibroblasts in rheumatoid arthritis","volume":"53","author":"Gui","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2022.108794_b0955","doi-asserted-by":"crossref","DOI":"10.3390\/cells8090953","article-title":"DNA Methylation as a Future Therapeutic and Diagnostic Target in Rheumatoid Arthritis","volume":"8","author":"Ciechomska","year":"2019","journal-title":"Cells."},{"key":"10.1016\/j.intimp.2022.108794_b0960","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3120391","article-title":"METTL3 Attenuates LPS-Induced Inflammatory Response in Macrophages via NF- \u03ba B Signaling Pathway","volume":"2019","author":"Wang","year":"2019","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.intimp.2022.108794_b0965","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/rheumatology\/kev312","article-title":"Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking I\u03baB kinase-dependent NF-\u03baB activation in rheumatoid fibroblast-like synoviocytes","volume":"55","author":"Xiao","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2022.108794_b0970","doi-asserted-by":"crossref","unstructured":"J.K. Park, Y.J. Jang, B.R. Oh, J. Shin, D. Bae, N. Ha, Y. il Choi, G.S. Youn, J. Park, E.Y. Lee, E.B. Lee, Y.W. Song, Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis, Arthritis Res Ther. 22 (2020). 10.1186\/S13075-020-02258-0.","DOI":"10.1186\/s13075-020-02258-0"},{"key":"10.1016\/j.intimp.2022.108794_b0975","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13075-020-02204-0","article-title":"The effect of nicotinamide adenine dinucleotide phosphate oxidase 4 on migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis","volume":"22","author":"Lee","year":"2020","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.intimp.2022.108794_b0980","first-page":"1588","article-title":"Genomic Responses of Mouse Synovial Fibroblasts During Tumor Necrosis Factor-Driven Arthritogenesis Greatly Mimic Those in Human Rheumatoid Arthritis, Arthritis","volume":"69","author":"Ntougkos","year":"2017","journal-title":"Rheumatol."},{"key":"10.1016\/j.intimp.2022.108794_b0985","doi-asserted-by":"crossref","unstructured":"G. hui Yang, C. Zhang, N. Wang, Y. Meng, Y. sheng Wang, Anacardic acid suppresses fibroblast-like synoviocyte proliferation and invasion and ameliorates collagen-induced arthritis in a mouse model, Cytokine. 111 (2018) 350\u2013356. 10.1016\/J.CYTO.2018.09.008.","DOI":"10.1016\/j.cyto.2018.09.008"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922002788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922002788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:44:01Z","timestamp":1761587041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922002788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":197,"alternative-id":["S1567576922002788"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108794","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update on novel therapeutic intervention in Rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108794","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108794"}}